China chip giants launch $577M 'patient capital' fund amid US curbs
Synopsis
A coalition anchored by memory chipmaker CXMT and Alibaba has quietly registered a $577 million 'patient capital' fund in Shanghai — a rare public-private hybrid designed to finance the long-cycle deep-tech R&D that US export controls have made strategically urgent for China.
Key Takeaways
ChangXin Memory Technologies (CXMT) and Alibaba Group Holding are among the backers of the newly registered Changzhi Hanhai Private Investment Fund .
The fund is valued at 3.91 billion yuan (US$577 million) and was registered in Shanghai's Pudong New Area last week.
Changxin Xinju Equity Investment (Anhui) Co , a CXMT subsidiary, holds the largest stake at 30 per cent ; Dongguan Trust follows at 29.4 per cent .
SSCI Leading Fund , backed by Shanghai state-owned capital, holds 20 per cent , reflecting the fund's hybrid public-private structure.
Semiconductor toolmaker Advanced Micro-Fabrication Equipment (AMEC) holds a 7.7 per cent stake, pointing to equipment self-sufficiency as a likely focus.
The fund is explicitly designed to provide long-term financing for deep-tech R&D that short-term venture capital typically bypasses.
China's leading technology companies, including memory chipmaker ChangXin Memory Technologies (CXMT) and e-commerce titan Alibaba Group Holding, have jointly launched a 3.91 billion yuan (US$577 million) private equity fund targeting the country's 'hard tech' sectors as US export controls on advanced technology continue to tighten.
What was announced
The Changzhi Hanhai Private Investment Fund was registered last week in Shanghai's Pudong New Area, according to data from corporate registry platform Qichacha and Chinese media reports. The fund is designed to provide so-called 'patient capital' — long-term financing for deep-tech research and development that conventional, short-term venture capital typically avoids.
Who holds the stakes
Changxin Xinju Equity Investment (Anhui) Co, a subsidiary of CXMT, holds the largest stake at 30 per cent. Dongguan Trust, a Guangdong-based trust services firm, controls 29.4 per cent, while SSCI Leading Fund, backed by Shanghai's state-owned capital, holds 20 per cent.
Hangzhou Haoyue Enterprise Management, an investment affiliate of Alibaba, contributes 10.2 per cent. Advanced Micro-Fabrication Equipment (AMEC), one of China's top domestic semiconductor toolmakers, accounts for the remaining 7.7 per cent.
Why it matters
The fund's structure — blending private tech giants with state-backed regional investment vehicles — reflects Beijing's broader strategy of mobilising both public and private capital to insulate its semiconductor supply chain from escalating US restrictions. CXMT is a key domestic alternative to foreign DRAM suppliers, while AMEC specialises in etch and deposition equipment that China has struggled to source internationally.
The 'patient capital' framing signals an intent to fund multi-year development cycles that are commercially unattractive to standard venture investors, particularly in chip fabrication equipment and advanced materials — areas where US and allied export controls have had the sharpest bite.
The competitive backdrop
China's semiconductor self-sufficiency drive has accelerated since 2022, when Washington imposed sweeping controls on advanced chip exports and equipment sales. State-directed funds, including the National Integrated Circuit Industry Investment Fund (the so-called 'Big Fund'), have channelled hundreds of billions of yuan into the sector. The Changzhi Hanhai vehicle adds a private-sector dimension to that effort, suggesting corporate stakeholders are increasingly willing to co-invest in strategically critical but commercially long-horizon projects.
What's next
The fund's deployment strategy and specific investment targets have not yet been publicly disclosed. Analysts will watch whether the vehicle directs capital toward chip equipment, advanced packaging, or materials — the three segments most acutely constrained by export controls. The involvement of AMEC and CXMT as anchor investors suggests semiconductor manufacturing tools and memory technology are likely priorities.
Point of View
Etch equipment, advanced materials — where US export controls have inflicted the most damage. What mainstream coverage often misses is the 'patient capital' framing, which implicitly acknowledges that commercial returns on these investments may be a decade away, making this as much a strategic hedge as a financial one. The inclusion of AMEC — a listed toolmaker already on Washington's radar — as a founding investor raises the question of whether the fund will attract further US scrutiny or secondary sanctions pressure on its participants. The broader pattern is clear: China is institutionalising long-horizon, state-adjacent capital structures to outlast the attrition strategy embedded in US tech controls.
NationPress
25 Jul 2026
Frequently Asked Questions
What is the Changzhi Hanhai Private Investment Fund?
The Changzhi Hanhai Private Investment Fund is a 3.91 billion yuan (US$577 million) private equity fund registered in Shanghai's Pudong New Area, backed by a coalition of Chinese tech companies and state-linked investors. It is designed to provide long-term 'patient capital' for deep-tech research and development in China's hard tech sectors.
Which companies are investing in China's new chip fund?
The fund's investors include CXMT (via its subsidiary Changxin Xinju Equity Investment), Dongguan Trust, the state-backed SSCI Leading Fund, Alibaba (via Hangzhou Haoyue Enterprise Management), and semiconductor equipment maker AMEC. Their stakes range from 7.7 per cent (AMEC) to 30 per cent (CXMT's subsidiary).
Why is China launching a 'patient capital' chip fund now?
The fund comes as US export controls on advanced chips and semiconductor equipment continue to tighten, restricting China's access to foreign technology. 'Patient capital' refers to long-term financing for deep-tech R&D that standard venture capital avoids due to lengthy payback periods — exactly the kind of development China needs to achieve semiconductor self-sufficiency.
What is CXMT and why is it significant?
ChangXin Memory Technologies (CXMT) is China's leading domestic DRAM memory chipmaker and a key alternative to foreign suppliers such as Samsung and SK Hynix. Its subsidiary holds the largest stake in the new fund at 30 per cent, underscoring its central role in China's memory chip self-reliance strategy.
How does this fund relate to China's broader semiconductor strategy?
The Changzhi Hanhai fund complements state-directed vehicles like China's National Integrated Circuit Industry Investment Fund (the 'Big Fund') by adding a private-sector co-investment layer. The hybrid structure — mixing corporate tech giants with state-backed regional funds — reflects Beijing's effort to mobilise all available capital for strategic technology development amid sustained US pressure.
